Comparison of two doses of intravenous immunoglobulin after allogeneic bone marrow transplants.
Intravenous immunoglobulin has been used after bone marrow transplants to prevent infections and acute graft-versus-host disease. However, the minimum dose required for protection is unknown. This may have significant economic implications. A multicenter randomized clinical trial compared the impact of two intravenous immunoglobulin doses on systemic infections and acute graft-versus-host disease in transplant recipients. Either 250 mg/kg or 500 mg/kg was given weekly from day -8 to day +111. Multivariate analysis was used to assess the effect of dose and other risk factors on event-free survival, systemic infection, and acute graft-versus-host disease. The two-dose cohorts had similar event-free survival and infection frequencies. The higher dose was associated with less acute graft-versus-host disease (P = 0.03).
Abdel-Mageed
A
A
University of Florida, Pediatric Hematology/Oncology, Gainesville 32610-0296, USA.
Graham-Pole
J
J
Del Rosario
M L
ML
Longmate
J
J
Ochoa
S
S
Amylon
M
M
Elfenbein
G J
GJ
Janiec
J
J
Jansen
J
J
Lazarus
H M
HM
D016026:Bone Marrow Transplantation / Q000009:adverse effects*; D018572:Disease-Free Survival; D006086:Graft vs Host Disease / Q000209:etiology / Q000517:prevention & control*; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000008:administration & dosage*; D015994:Incidence; D014184:Transplantation, Homologous; D014777:Virus Diseases / Q000517:prevention & control*
D016756:Immunoglobulins, Intravenous